{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:42:35Z","timestamp":1793727755284,"version":"4.6.1"},"reference-count":19,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"1","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2020,1,1]]},"abstract":"<jats:sec><jats:title>PURPOSE<\/jats:title><jats:p> In this multicenter phase II trial, we evaluated atezolizumab combined with bevacizumab in patients with advanced renal cell carcinoma (RCC) with variant histology or any RCC histology with \u2265 20% sarcomatoid differentiation. <\/jats:p><\/jats:sec><jats:sec><jats:title>PATIENTS AND METHODS<\/jats:title><jats:p> Eligible patients may have received previous systemic therapy, excluding prior bevacizumab or checkpoint inhibitors. Patients underwent a baseline biopsy and received atezolizumab 1,200 mg and bevacizumab 15 mg\/kg intravenously every 3 weeks. The primary end point was overall response rate (ORR) by RECIST version 1.1. Additional end points were progression-free survival (PFS), toxicity, biomarkers of response as determined by programmed death-ligand 1 (PD-L1) status, and on-therapy quality-of-life (QOL) metrics using the Functional Assessment of Cancer Therapy Kidney Symptom Index-19 and the Brief Fatigue Inventory. <\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p> Sixty patients received at least 1 dose of either study agent; the majority (65%) were treatment na\u00efve. The ORR for the overall population was 33% and 50% in patients with clear cell RCC with sarcomatoid differentiation and 26% in patients with variant histology RCC. Median PFS was 8.3 months (95% CI, 5.7 to 10.9 months). PD-L1 status was available for 36 patients; 15 (42%) had \u2265 1% expression on tumor cells. ORR in PD-L1\u2013positive patients was 60% (n = 9) v 19% (n = 4) in PD-L1\u2013negative patients. Eight patients (13%) developed treatment-related grade 3 toxicities. There were no treatment-related grade 4-5 toxicities. QOL was maintained throughout therapy. <\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p> In this study, atezolizumab and bevacizumab demonstrated safety and resulted in objective responses in patients with variant histology RCC or RCC with \u2265 20% sarcomatoid differentiation. This regimen warrants additional exploration in patients with rare RCC, particularly those with PD-L1\u2013positive tumors. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.19.01882","type":"journal-article","created":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T20:59:15Z","timestamp":1573678755000},"page":"63-70","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":135,"title":["Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and\/or Sarcomatoid Features"],"prefix":"10.1200","volume":"38","author":[{"given":"Bradley A.","family":"McGregor","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana R.","family":"McKay","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Braun","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian","family":"Werner","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Gray","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdallah","family":"Flaifel","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Signoretti","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle S.","family":"Hirsch","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Steinharter","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad","family":"Bakouny","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Flippot","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao X.","family":"Wei","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atish","family":"Choudhury","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Kilbridge","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon J.","family":"Freeman","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliezer M.","family":"Van Allen","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren C.","family":"Harshman","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"McDermott","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulka","family":"Vaishampayan","sequence":"additional","affiliation":[{"name":"Karmanos Cancer Institute, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1601333"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1101\/gr.131110.111"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200404000-00002"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2017.03.004"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28151"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00515-X"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.10.049"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30723-8"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2008.08.013"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.3015"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0116"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu445"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.06.043"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.4809"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30907-0"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816047"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.19.01882","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T10:24:07Z","timestamp":1653819847000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.19.01882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1,1]]}},"alternative-id":["10.1200\/JCO.19.01882"],"URL":"https:\/\/doi.org\/10.1200\/jco.19.01882","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,1]]},"assertion":[{"value":"2019-10-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}